BRPI0410663B8 - compostos de hidroxiamidina e hidroxiguanidina e seus usos - Google Patents

compostos de hidroxiamidina e hidroxiguanidina e seus usos

Info

Publication number
BRPI0410663B8
BRPI0410663B8 BRPI0410663A BRPI0410663A BRPI0410663B8 BR PI0410663 B8 BRPI0410663 B8 BR PI0410663B8 BR PI0410663 A BRPI0410663 A BR PI0410663A BR PI0410663 A BRPI0410663 A BR PI0410663A BR PI0410663 B8 BRPI0410663 B8 BR PI0410663B8
Authority
BR
Brazil
Prior art keywords
compounds
hydroxyamidine
urokinase
hydroxyguanidine
relates
Prior art date
Application number
BRPI0410663A
Other languages
English (en)
Inventor
Clement Bernd
Wosikowski Katja
Bürgle Markus
Sperl Stefan
Schmalix Wolfgang
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of BRPI0410663A publication Critical patent/BRPI0410663A/pt
Publication of BRPI0410663B1 publication Critical patent/BRPI0410663B1/pt
Publication of BRPI0410663B8 publication Critical patent/BRPI0410663B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182Radicals derived from carboxylic acids
    • C07D295/185Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase. a presente invenção refere-se a novos compostos para inibição do ativador de plasminogênio uroquinase (upa), que apresentam alta biodisponibilidade e administrabilidade oral, e também ao uso dos mesmos como compostos terapêuticos ativos para o tratamento de distúrbios associados à uroquinase ou/e receptores de uroquinase tais como, por exemplo, tumores e metastatização. a invenção refere-se em particular a compostos que contêm grupos hidroxiamidina ou hidroxiguanidina.
BRPI0410663A 2003-05-26 2004-05-26 compostos de hidroxiamidina e hidroxiguanidina e seus usos BRPI0410663B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10323898A DE10323898A1 (de) 2003-05-26 2003-05-26 Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10323898.0 2003-05-26
PCT/EP2004/005682 WO2004103984A1 (de) 2003-05-26 2004-05-26 Hydroxyamidin- und hydroxyguanidin-verbindungen als urokinase-hemmstoffe

Publications (3)

Publication Number Publication Date
BRPI0410663A BRPI0410663A (pt) 2006-06-20
BRPI0410663B1 BRPI0410663B1 (pt) 2019-05-21
BRPI0410663B8 true BRPI0410663B8 (pt) 2021-05-25

Family

ID=33461890

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410663A BRPI0410663B8 (pt) 2003-05-26 2004-05-26 compostos de hidroxiamidina e hidroxiguanidina e seus usos

Country Status (15)

Country Link
US (3) US7608623B2 (pt)
EP (2) EP1628965B1 (pt)
JP (1) JP4621676B2 (pt)
CN (2) CN1795183B (pt)
AU (2) AU2004240771B2 (pt)
BR (1) BRPI0410663B8 (pt)
CA (1) CA2526989C (pt)
DE (1) DE10323898A1 (pt)
DK (1) DK1628965T3 (pt)
ES (1) ES2550611T3 (pt)
HU (1) HUE025940T2 (pt)
MX (1) MXPA05012675A (pt)
PL (1) PL1628965T3 (pt)
PT (1) PT1628965E (pt)
WO (1) WO2004103984A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7838560B2 (en) * 2002-03-11 2010-11-23 The Medicines Company (Leipzig) Gmbh Urokinase inhibitors, production and use thereof
DE10301300B4 (de) * 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10342108A1 (de) * 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
DE102004057195A1 (de) 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
EP2087885A1 (en) 2005-06-24 2009-08-12 Wilex AG Use of urokinase inhibitors for the treatment and /or prevention of neuropathological diseases
DE102006050672A1 (de) * 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
JPWO2008143342A1 (ja) * 2007-05-23 2010-08-12 大日本住友製薬株式会社 3−アミノ−2,5−ジオキソピロリジン誘導体の製造方法
DE102008007381A1 (de) 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten
US9662308B2 (en) 2008-02-01 2017-05-30 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg Orally bioavailable pentamidine prodrugs for the treatment of diseases
DE102008007440A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
CN102319241B (zh) * 2011-07-06 2016-02-10 中山大学 一种针对ccl18靶标的化合物在制备抗乳腺癌药物中的应用
DE102011108346A1 (de) * 2011-07-25 2013-01-31 Philipps-Universität Marburg Verwendung von Hemmstoffen der TMPRSS2 als Arzneimittel
AU2016336133B2 (en) 2015-10-06 2021-02-25 Redhill Biopharma Ltd. Combination therapies for treating cancer
KR20200031567A (ko) * 2017-07-21 2020-03-24 레드힐 바이오파마 엘티디 비암성 의학적 질환의 치료를 위한 wx-uk1 및 그의 프로드러그 wx-671의 용도
IL295658A (en) 2020-03-10 2022-10-01 Redhill Biopharma Ltd Treatment of coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN114105910B (zh) * 2021-11-02 2024-04-12 北京悦康科创医药科技股份有限公司 一种羟基脒基苯丙氨酸衍生物、药物组合物与用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE4321444A1 (de) 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
JP2852192B2 (ja) 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・1989(フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング) uPARのドメイン2+3のuPA結合部位および抗体
DE59903981D1 (de) 1998-07-20 2003-02-13 Wilex Ag Neue urokinase-inhibitoren
AU9059798A (en) * 1998-09-18 2000-04-10 Pentapharm Ag Urokinase inhibitors
US6410005B1 (en) * 2000-06-15 2002-06-25 Pmd Holdings Corp. Branched/block copolymers for treatment of keratinous substrates
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
US20030125233A1 (en) 2000-06-27 2003-07-03 Peter Carmeliet Use of urokinase inhibitors for the treatment and/or prevention of pulmonary hypertension and/or cardiac remodelling
DE60034447T2 (de) 2000-08-11 2008-02-14 Wilex Ag Nicht-kovalente Urokinase-und Angiogenese-Inhibitoren
NZ518195A (en) 2000-08-11 2005-04-29 Corvas Int Inc Non-covalent inhibitors of urokinase and blood vessel formation
CA2428191A1 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US20040248111A1 (en) * 2001-02-07 2004-12-09 Gunther Metz Screening method using solid supports modified with self-assembled monolayers
WO2002074756A2 (de) * 2001-03-21 2002-09-26 Pentapharm Ag Urokinase-inhibitoren
CH695999A5 (de) * 2002-02-28 2006-11-15 Wilex Ag Verfahren zur Herstellung von 3- Amidinophenylalanin-Derivaten.
AU2003253326A1 (en) * 2002-07-25 2004-02-16 Wilex Ag Method for the production of phenylalanine derivatives

Also Published As

Publication number Publication date
CN1795183A (zh) 2006-06-28
EP1628965A1 (de) 2006-03-01
CA2526989C (en) 2012-12-04
DE10323898A1 (de) 2004-12-23
WO2004103984A1 (de) 2004-12-02
AU2009201816A1 (en) 2009-05-28
CA2526989A1 (en) 2004-12-02
US7807681B2 (en) 2010-10-05
US20080261998A1 (en) 2008-10-23
US7608623B2 (en) 2009-10-27
AU2004240771B2 (en) 2009-02-19
EP1628965B1 (de) 2015-07-22
BRPI0410663A (pt) 2006-06-20
BRPI0410663B1 (pt) 2019-05-21
PL1628965T3 (pl) 2016-02-29
PT1628965E (pt) 2015-11-04
ES2550611T3 (es) 2015-11-11
JP2007513062A (ja) 2007-05-24
CN101791394A (zh) 2010-08-04
AU2004240771A1 (en) 2004-12-02
JP4621676B2 (ja) 2011-01-26
MXPA05012675A (es) 2006-02-22
US20060142305A1 (en) 2006-06-29
EP2243774A1 (de) 2010-10-27
HUE025940T2 (en) 2016-05-30
DK1628965T3 (en) 2015-11-02
CN1795183B (zh) 2010-04-28
US20100068272A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0410663A (pt) compostos de hidroxiamidina e hidroxiguanidina como inibidores de uroquinase
BRPI0410563B8 (pt) compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
UY28059A1 (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos.
ECSP034773A (es) Pirazolopirimmidinas como agentes terapeuticos
MY143466A (en) Inhibitors of tyrosine kinases
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
NO20082414L (no) Inhibitorer av AKT-aktivitet
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
NO20044261L (no) Indazoler substituerte med en anticanceros aktivitet
DE602007004618D1 (de) Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
BRPI0514395A (pt) uso terapêutico de inibidores de rtp801
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BR0212141A (pt) Inibidores de protease de cisteìna com estrutura 2-ciano-4-amino-pirimidina e atividade inibidora de catepsina k para o tratamento de inflamações e outras doenças
BR0306988A (pt) Piridazinonas substituìdas como inibidores de p38
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
UY27592A1 (es) Nuevo uso
BR0209518A (pt) Novos derivados arilheteroalquilamina
BRPI0417158A (pt) composto, composição farmacêutica, uso de um composto, método para prevenir, tratar ou melhorar uma doença ou condição associada com angiogênese desregulada, e, métodos para tratar ou melhorar cáncer, para reduzir o potencial metastático de um tumor, e para tratar ou melhorar tumores, e uma condição ou doença
IL229136A0 (en) mek inhibitors and methods of using them
DE60305484D1 (de) Verbindungen und deren verwendung als 5-ht inhibitore

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: WILEX AG (DE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080117818/RJ DE 08/09/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 21/05/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2776 DE 19-03-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.